OKEP 20 Feb'15

1.

Name:

2.

Territory:

3.

Email Id:

4.

First anti-muscarinic agent, used, for the treatment of overactive bladder (OAB) is?

a) oxybutynin

b) Tolterodine

c) Phenoxybenzamine

d) Mirabegron

5.

Which of the following not an anti-muscarinic agent can be used in LUTS?

a) Oxybutynin

b) Solifenacin

c) Tolterodine

d) Tamsulosin

e) Fesoterodine

f) All of the above

6.

Which of the following drug used for the treatment of OAB causes high incidence of dry mouth?

a) oxybutynin

b) Tolterodine

c) fesoterodine

d) mirabegron

7.

As per this review article which of the following statement is true among the following?

a) Solifenacin is superior to tolterodine ER in reducing the numbers of urgency episodes/24 h, urgency incontinence episodes/24 h, incontinence episodes/24 h, and pad use due to flexible dosing

b) Fesoterodine 4 mg and tolterodine ER 4 mg had a similar safety profile

c) Fesoterodine 8 mg has significantly simmilar rates of dry mouth and dry eyes in comparison to tolterodine 4 mg

d) All are correct

8.

In OPERA Study, OPERA is?

a) Overactive Bladder: Performance of Extended Release Agents

b) It is name of clinical trial

c) This compare efficacy and tolerability of tolterodine ER (4 mg daily) and oxybutynin (10 mg daily)

d) a & c correct

e) All are correct

9.

Which of the following is not true for a multicenter, double-blind, randomized placebo controlled study in 1529 patients with OAB for tolterodine?

a) A 71% mean reduction in urgency incontinence episodes was found in the tolterodine ER group compared to a 60% reduction in the tolterodine IR group

b) The incidence of dry mouth was 30% for tolterodine ER versus 23% for tolterodine IR.

c) The incidence of other adverse events such as dizziness (ER 2% vs. IR 2%), constipation (ER 7% vs. IR 6%) and somnolence (ER 3% vs. IR 3%) were similar between the treatment groups and comparable with placebo.

d) All are true

10.

Which of the following Beta3-receptor agonists can be used for treatment of urge urinary incontinence?

a) oxybutynin

b) Tolterodine

c) fesoterodine

d) mirabegron

11.

Which of following is not a symptom of storage LUTS ?

a) Nocturia

b) Urgency

c) Urinary incontinence

d) Intermittency

12.

The STAR study is for?

a. oxybutynin

b. Tolterodine

c. fesoterodine

d. Combination of Tolterodine and Tamsulosin

e. Solifenacin